Clinical Trials
8 trialsNCT02567435 2026-05-27
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00980460 2026-05-04
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01646021 2018-01-19
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00117598 2015-03-30
OPTIMAL
Pfizer
Phase 3 Completed
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT00065468 2012-10-25
ARCC
Pfizer
Phase 3 Completed
NCT00083993 2011-11-08
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Terminated